Kornimate/medical-research-clean huggingface dataset:
neoadjuvant anti-pd-1 antibody (toripalimab) or combined with chemotherapy in hnscc patients

Conditions: Head and Neck Squamous Cell Carcinoma

Summary: this study evaluate either toripalimab or combined with chemotherapy as neoadjuvant treatment for patients with head and neck squamous cell carcinoma. participants in arm a receive toripalimab, in arm b receive toripalimab plus pc (paclitaxel and carboplatin), arm c with toripalimab plus modified tpf(paclitaxel and cisplatin and 5-fu).


Eligibility criteria:
inclusion criteria: * confirmed pathologic or cytologic diagnosis of squamous cell carcinoma of head and neck; * resectable or potentially resectable lesion; * ecog ps 0-1; * age \>18 years old; * at least one target lesion according to recist 1.1; * proper function of the cardiovascular system, liver, kidney and bone marrow for receiving chemotherapy and surgery; exclusion criteria: * distant metastasis; * second malignancy within 5 years; * nasopharyngeal carcinoma; * active autoimmune diseases; * hiv infected; * required prednisone dose \>=10mg daily; * heart attack within 6 months; * stroke within 6 months; * other conditions that investigators consider the patients are not suitable for pd-1antibody;

Keywords: hnscc pd-1 antibody neoadjuvant major pathologic response
letrozole versus laparoscopic ovarian drilling in polycystic ovary syndrome

Conditions: Infertility

Summary: polycystic ovary syndrome is the major cause of anovulatory infertility. clomiphene citrate is the most commonly used oral agent for ovulation induction in this group, but there are some drawbacks with the use of it.


Eligibility criteria:
inclusion criteria: * history of at least one year of infertility either primary or secondary. * body mass index: 25-35 * normal fallopian tubes * normal semen analysis of the husband * women who will accept to participate in the study exclusion criteria: * body mass index above 35 * contraindication to general anesthesia * previous laparoscopic drilling * presence of other causes of infertility * women who had received metformin, gonadotrophin, oral contraceptives or other hormonal drugs during the preceding 6 months * women who intended to start a diet program * women who will refuse to participate in the study.
anlotinib for advanced and refractory natural killer /t-cell lymphoma

Conditions: Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

Summary: the purpose of this study is to evaluate the efficacy and safety of anlotinib in patients with stage iv extranodal natural killer/t-cell lymphoma, nasal type.

extranodal natural killer/t-cell lymphoma (enktcl), nasal type, is a rare subtype of non-hodgkin lymphoma (nhl) with relatively high incidence in china. l-asparaginase based chemotherapy improved overall response and prolonged the long-term survival for patients with stage iv. but the treatment for the patients with advanced disease and resistant to l-asparaginase based chemotherapy has not been established. the overall survival for these patients are very poor. this study is designed to evaluate the efficacy and safety of anlotinib in patients with stage iv enktcl and refractory to l-asparaginase based chemotherapy.

Eligibility criteria:
inclusion criteria: * pathological diagnosis of extranodal natural killer/t-cell lymphoma, nasal type. * stage iv disease and resistant to l-asparaginase-based combined chemotherapy.(definition of l-asparaginase resistance: progression during treatment or no response to treatment). * eastern cooperative oncology group (ecog ) performance status 0\~3. * preserved organ functions for: absolute neutrophil counter (anc)\>1.0×109/l, platelet\>50×109/l, hemoglobin\>80g/l, total bilirubin (tbil)\<2×uln, alanine transaminase (alt)\<2×uln, normal serum creatinine，fibrinogen≥1.0g/l, lvef≥50%. * signed informed consented. exclusion criteria: * patients with a disease resistant to l-asparaginase but may benefit from a radiotherapy. * hiv, hepatitis virus c (hcv), or active hepatitis virus b (hbv) infection with hbv dna≥105 copies/ml. * significant complications: autoimmune disease, severe infection, or liver cirrhosis, hemophagocytic lymphohistiocytosis, disseminated intravascular coagulation, uncontrolled hypertension or diabetes, hemorrhagic or thrombotic events within 6 months. * mental disorders. * pregnant or lactation * peptic ulcer * enrolled in other trial treatment

Keywords: anlotinib l-asparaginase resistant
pallidal stimulation in patients with post-anoxic and idiopathic dystonia

Conditions: Dystonia

Summary: bilateral pallidal stimulation is effective in the treatment of patients with generalised idiopathic dystonia. the aim of this study is to evaluate the efficacy of bilateral pallidal stimulation in patients with post-anoxic generalised dystonia or non-generalised primary dystonia.

evaluate the effect of bilateral pallidal stimulation on the motor disability of patients with post-anoxic generalised dystonia or primary dystonia.

Eligibility criteria:
inclusion criteria: * post-anoxic generalised dystonia * idiopathic non-generalised dystonia * disease duration \> 1 year exclusion criteria: * contraindication to magnetic resonance imaging (mri) * mini-mental status (mms) \< 24 * severe psychiatric disorder

Keywords: dystonia deep brain stimulation globus pallidus post-anoxic dystonia
preemptive analgesic efficacy of parecoxib for reducing postoperative pain in gynecological surgery

Conditions: Preemptive Analgesia; Gynecological Surgery; Postoperative Pain; Parecoxib

Summary: the research is to test the preemptive analgesic efficacy of parecoxib drug in gynecological surgery by comparing parecoxib drug and nss administration 15 min before starting the surgery which the result of postoperative pain score is interpret by visual analog scale index

the research is working on testing the preemptive analgesic efficacy of parecoxib drug in gynecological surgery whether its can reduce postoperative pain score, reduce total opioid consumption in first 24 hour postoperation and reduce postoperation hospital length stay. patients who are undergoing gynecological surgery is recruited to the research project while they admit in the hospital for preoperative preparation, in each type of surgery groups (1.total abdominal hysterectomy 2. adnexal surgery 3. surgical staging) will divided in to 2 groups which is experimental group (parecoxib) and control group (normal saline). the experimental group will have parecoxib administration 15 min before starting the surgery and control group will have normal saline administration 15 min before starting the surgery as same, the primary result is postoperative pain score which is interpreted by visual analog scale index at 2,6,12,24 hour postoperation, the patients will get opioid drug (morphine) for pain control depending on pain score index they inform, if pain score \>7: morphine 0.075 mg/kg iv, if pain score 5 : morphine 0.05mg/kg iv, if pain score \<5 : no morphine given. lastly the side effect of parecoxib drug will be observed and postoperative hospital length stay of each patient will be recorded

Eligibility criteria:
inclusion criteria: * female patients age between 18-70 year-old, who participate in explor lap gynecological surgery (hysterectomy, adnexal surgery and surgical stagings) using general anesthesia technique * american society of anesthesiologists physical status grade i-ii * capable to communicate in thai language exclusion criteria: * allergic to nsaids and opioid * allergic to parecoxib drug * underlying neuropathic pain * pregnant woman or woman who undergoes breast feeding * uncontrolled hypertension disease, bp \>160/110 at admission date * underlying ischemic heart disease, ischemic stroke or peripheral arterial disease * history status post coronary artery bypass grafting * patients who take aspirin within 7 days before surgery date * had underlying which is contraindiated to nsaids drug such as gastritis, history of gi ulcer, chronic kidney disease (cr clearance \< 30ml/min), liver cirrhosis (child-pugh class b or above/ serum albumin \< 25 g/l) * patients who had nsaids drug while admit in hospital for preparing the operation before surgery date

Keywords: preemptive analgesia gynecological surgery parecoxib postoperative pain
cranberry juice for preventing bacteria in urine during pregnancy

Conditions: Urinary Tract Infection; Bacteriuria

Summary: the purpose of this study is to determine the amount of cranberry juice that is most effective in preventing a condition in pregnant women that often leads to urinary tract infections (utis).

asymptomatic bacteriuria (asb) infection, a condition in which a large number of bacteria are present in the urine, often precedes the development of symptomatic utis. utis are common among women and may create complications during pregnancy. by incorporating cranberry juice into their diets, pregnant women may be able to lower their risk for utis caused by asb, and cranberry juice may also prevent preterm labor and birth. this study will determine the cranberry juice-containing regimen that will work best for preventing asb in pregnant women. for the duration of their pregnancy, participants in this study will be randomly assigned to one of three treatment arms: cranberry juice once a day, cranberry juice three times a day, or a placebo beverage three times a day. the level of bacteria in their urine will be measured at monthly study visits. women who test positive for a uti will receive oral antibiotic therapy. all women will be monitored throughout their pregnancies for utis and other related complications.

Eligibility criteria:
inclusion criteria: * intrauterine pregnancy * mother and fetus in good health * mother pregnant for 16 weeks or less exclusion criteria: * suspected nonviable or ectopic pregnancy * mother plans to terminate pregnancy * antimicrobial therapy, for reasons other than urinary tract infections, within 2 weeks prior to study start * significant underlying medical complications that may interfere with the study

Keywords: vaccinium macrocarpon asymptomatic bacteriuria
effects of endurance training on patients with reduced left ventricular ejection fraction (lvef) and cardiac resynchronisation therapy especially for cardiac arrhythmias

Conditions: Heart Failure; Cardiac Resynchronisation Therapy; Sudden Cardiac Death

Summary: a severely reduced left ventricular ejection fraction is associated with increased mortality due to pump failure as well as to malignant ventricular arrhythmia. we hypothesize that targeted training may lead to improved survival and to increased parameters of risk stratification for malignant arrhythmia. additionally, the training may lead to an improved psychological and mental condition of the patients


Eligibility criteria:
inclusion criteria: * crt device exclusion criteria: * refused informed consent
effects of whole-body vibration training on body composition in adolescents with and without down syndrome

Conditions: Down Syndrome

Summary: the main aims of the present project include 1) to study the longitudinal effects of whole-body vibratory exercise on bone metabolism in adolescents with and without ds and 2) to evaluate whether a low frequency vibratory training program consisting of 3 sessions per week for 9 months (each vibratory session last approximately 10 minutes and includes 5-6 bouts of 1 min with 1 min rest between bouts) can improve bone development in these populations. finally, and additional aim of the project is 3) to determine how long these effects may last after the end of the intervention.


Eligibility criteria:
inclusion criteria: * both groups: ages 10 - 19. * both groups: parental/guardian permission (informed consent) and if appropriate, child verbal assent. * down syndrome group only: diagnosis of down syndrome. exclusion criteria: * taking medication affecting bone. * non-caucasian.
azisast study: azithromycin in severe asthma study

Conditions: Asthma

Summary: the purpose of this study is to evaluate the efficacy, safety and cost-effectiveness of azithromycin as add-on therapy in adult subjects with severe persistent asthma, who remain inadequately controlled despite gina (2006) step 4 or 5 therapy.


Eligibility criteria:
inclusion criteria: 1. patients who have given written informed consent 2. males or females of any race 3. 18-75 years of age 4. with the diagnosis of persistent asthma ≥ 1 year duration at screening and a history consistent with gina step 4 or 5 clinical features 5. receiving high dose ics plus inhaled laba for at least 6 months prior to screening 6. patients who have suffered multiple (i.e. at least two) independent documented severe asthma exacerbations within the previous 12 months 7. patients must be never-smokers or ex-smokers with a smoking history of ≤ 10 pack-years. exclusion criteria: 1. females who are pregnant or who are breastfeeding 2. patients with severe bronchiectasis 3. patients with active tuberculosis or non-tuberculous mycobacterial infections (ntm) 4. patients with significant underlying medical conditions (e.g. infection, hematological disease, malignancy, neurologic, renal, hepatic, coronary heart disease or other cardiovascular disease, endocrinologic or gastrointestinal disease) within the previous 3 months 5. who are unable to perform spirometry or complete a patient diary or complete questionnaires 6. patients with known hypersensitivity to azithromycin or other macrolide antibiotics 7. patients who's heart rate corrected qt interval is prolonged 8. patients who have - in the judgement of the investigator - a clinically relevant laboratory abnormality 9. patients currently treated with macrolide antibiotics or recent macrolide treatment (in the past twelve weeks) 10. anti-ige treatment

Keywords: inadequately controlled severe asthma
mulligan mobilizations and mckenzie exercises along with neural mobilizations in cervical spondylosis

Conditions: Spondylosis

Summary: cervical pain is one of the common problem among general population. however, cervical spondylosis may cause unavoidable neck pain and range limitations due to wear and tear changes in the cervical spine. this condition can further lead to dysfunction and neuro musculoskeletal symptoms. literature suggests the use of mulligan therapy, mckenzie exercises and neural mobilizations in spondylosis. according to author's knowledge there is limited evidence regarding effects of specific treatment approach.

a randomized control trial will be conducted among 80 patients with cervical spondylosis having age group 40 to 60 years. the non-probability purposive sampling technique will be used to recruit on the basis of study criteria. the study settings will be dow university of health sciences, karachi pakistan. after taking informed consent all the patients will be randomized into two groups (a, b). group a will receive mulligan with upper limb movement of involved side, group b will receive mckenzie exercises and neural mobilizations. patients will be evaluated at baseline and after four weeks of treatment by using a goniometer, numerical pain rating scale (nprs), and neck disability index (ndi) for cervical range of motions, pain intensity and neck disability respectively. there will be twelve sessions of treatment with thrice a week. duration of each session will be thirty minutes. all the data will be entered and analyzed through statistical package of social sciences version 24. descriptive analysis will be performed for both continuous and categorical data. inferential statistics will be performed to compare pain, disability index and range of motion between group and within group. the level of significance will be considered as 0.05.

Eligibility criteria:
inclusion criteria: * 40 - 60 years old adults. * diagnosed and referred cases of cervical spondylosis and both males and females are included. * unilateral radiculopathy pain c5-c8 and t1. * individuals whose spurling's and distraction test is positive. * patients with nprs \> 3/10 score. * patients with ipsilateral cervical rotation less than 60 degrees. exclusion criteria: individuals with history of; * cervical or shoulder girdle trauma. * any specific pathology or red flags (diplopia, dizziness, drop attacks, dysarthria, dysphagia) * cervical myelopathy * neoplastic lesions * vertebral artery insufficiency * upper cervical ligamentous instability, * spondylolisthesis * hypermobile cervical spine * cervical fracture inflammatory * cardiac or severe psychiatric disease.

Keywords: cervical spondylosis mckenzie nprs ndi mulligan with mobilization universal goniometer
preoperative chemoradiation for glioblastoma

Conditions: Glioblastoma

Summary: trial to determine the safety of neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.

prior to any definitive treatment and after enrollment, the patient will undergo stereotactic biopsy of the lesion to confirm the histology of the lesion and to determine methylated methylguanine methyltransferase (mgmt) status. standard image-guided stereotactic technique will be used. patients will be treated with conformal radiation therapy. temozolomide will be given from the day prior to radiation therapy through the last day of radiation therapy. 4-6 weeks after radiation therapy the patient will undergo craniotomy and maximal safe resection. temozolomide will continue beginning 4 weeks after surgery. imaging: mri within 2 weeks prior to the start of the protocol. mri at 4 weeks after chemoradiation therapy and prior to surgery. mri within 48 hours after surgery. mri after every 2 cycles of chemotherapy and then every 2 months until progression, up to 2 years.

Eligibility criteria:
inclusion criteria: * mri lesions of the brain that have a high probability of being glioblastoma in a potentially resectable location in the brain (the primary study population) * who performance status 0-2 (to allow comparison to historical controls) * adequate hematological parameters: (for safety because of neutropenia from the temozolomide) * consent can be obtained from the patient, and if the patient cannot give consent then from the medical power of attorney and if one is not assigned, then the nearest relative (required to obtain consent) * able to have mri scans (secondary endpoint is mri scan characteristics) * willing to have radiation treatment at a participating center (homogeneity of treatment parameters) * ages 18-80 exclusion criteria: * unresectable tumor * absolute neutrophil count (anc) less than 1,200/μl * hemoglobin less than 9.0g/dl * platelet count less than 100,000/μl

Keywords: glioblastoma temozolomide radiation therapy radiotherapy surgery pre-operative neoadjuvant
bradycardia pacemaker with av interval modulation for blood pressure treatment

Conditions: Hypertension; Hypertension, Systolic; Hypertension, Essential

Summary: a prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (avim) algorithm downloaded into a dual-chamber medtronic astra/azure pacemaker.

the study will be conducted in three phases: 1) screening phase, 2) double-blind randomized phase (1 year), and 3) unblinded phase (2 years). patients who are scheduled to undergo implantation of a, or already have an implanted, de novo astra/azure pacemaker system, who also have uncontrolled hypertension may be screened for inclusion into this study. all eligible subjects will receive the avim ramware and be randomized 1:1 to either have avim therapy turned on or turned off. all subjects will continue to receive antihypertensive drug therapy.

Eligibility criteria:
inclusion criteria: 1. patient has or is indicated for a de novo dual chamber pacemaker. patient informed consent must be obtained within 30 days prior to a planned de novo implant of a medtronic astra/azure dual chamber pacemaker system or up to 365 days after 2. on a stable antihypertension treatment regimen with 1, 2, or 3 classes of antihypertensive drugs 3. office sbp ≥140 mmhg and \<180 mmhg 4. average 24-hour asbp ≥130 mmhg and \<170 mmhg exclusion criteria: 1. lvef \<50% 2. nyha class ii-iv 3. history of cerebrovascular accident (cva) or transient ischemic attack (tia) within 6 months 4. myocardial infarction (mi) within 3 months 5. prior percutaneous or surgical coronary, carotid, or endovascular intervention within 3 months 6. persistent or permanent atrial fibrillation 7. mitral valve regurgitation greater than grade 3 8. aortic stenosis with a valve area less than 1.5 cm2 9. has an active or prior device-based anti-hypertensive treatment (e.g., renal denervation procedure, baroreflex activation therapy) 10. has an existing active cardiac device or neurostimulator other than the recent astra/azure pacemaker implant
mood patient powered research network (moodnetwork)

Conditions: Mood Disorders; Bipolar Disorder; Major Depressive Disorder; Depression

Summary: the moodnetwork, a patient-powered research network (pprn), is one of 18 pprns participating in patient-centered outcomes research institute's (pcori) pcornet network. its objective is to improve the nation's capacity to conduct comparative effectiveness research that reflects questions of greatest importance to patients and other stakeholders. a robust data infrastructure will be built that, in phase one, allows participants to contribute data, including those from participant questionnaires, visualize their own health information in intuitive and helpful ways, and share their aggregated de-identified health information within and outside of the network.


Eligibility criteria:
inclusion criteria: * english speaking * valid email address * self-identify as having a mood disorder exclusion criteria: * under 18 years of age